18F FDG PET/CT and head and neck cancer: Patient management and outcomes

Sara Sheikhbahaei; Charles Marcus; Rathan M. Subramaniam

doi:10.1016/j.cpet.2014.12.001

18F FDG PET/CT and head and neck cancer: Patient management and outcomes

Sara Sheikhbahaei, Charles Marcus, Rathan M. Subramaniam

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.

Original language	English (US)
Pages (from-to)	125-145
Number of pages	21
Journal	PET Clinics
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.cpet.2014.12.001
State	Published - Apr 1 2015

Keywords

Head and neck squamous cell cancer
Management change
Prognosis
Survival outcome
Therapy response

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2014.12.001

Cite this

@article{579b91b73bba4a3aa592ca7d3671affd,

title = "18F FDG PET/CT and head and neck cancer: Patient management and outcomes",

abstract = "There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.",

keywords = "Head and neck squamous cell cancer, Management change, Prognosis, Survival outcome, Therapy response",

author = "Sara Sheikhbahaei and Charles Marcus and Subramaniam, {Rathan M.}",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.cpet.2014.12.001",

language = "English (US)",

volume = "10",

pages = "125--145",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - 18F FDG PET/CT and head and neck cancer

T2 - Patient management and outcomes

AU - Sheikhbahaei, Sara

AU - Marcus, Charles

AU - Subramaniam, Rathan M.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.

AB - There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.

KW - Head and neck squamous cell cancer

KW - Management change

KW - Prognosis

KW - Survival outcome

KW - Therapy response

UR - http://www.scopus.com/inward/record.url?scp=84926225112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926225112&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2014.12.001

DO - 10.1016/j.cpet.2014.12.001

M3 - Review article

C2 - 25829083

AN - SCOPUS:84926225112

SN - 1556-8598

VL - 10

SP - 125

EP - 145

JO - PET Clinics

JF - PET Clinics

IS - 2

ER -

18F FDG PET/CT and head and neck cancer: Patient management and outcomes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this